Brief: Immunocore Says Co Increasing Commercial Access to KIMMTRAK Globally

Immunocore Holdings

05/01/2024 12:13

Jan 5 (Reuters) - Immunocore Holdings PLC  IMCR.O :
    * IMMUNOCORE ANNOUNCES STRATEGIC PRIORITIES AND PIPELINE
EXPANSION
AHEAD OF 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
PRESENTATION
    * IMMUNOCORE HOLDINGS PLC - DATA FROM IMC-M113V PHASE 1
CLINICAL
TRIAL IN PEOPLE LIVING WITH HIV EXPECTED IN SECOND HALF OF 2024
    * IMMUNOCORE HOLDINGS PLC - SUBMITTED CTA FOR IMC-R117C, A
FIRST-IN-CLASS IMMTAC TARGETING PIWIL1 FOR COLORECTAL AND OTHER
GASTROINTESTINAL CANCERS
    * IMMUNOCORE HOLDINGS PLC - INCREASING COMMERCIAL ACCESS TO
KIMMTRAK (TEBENTAFUSP-TEBN) GLOBALLY
    * IMMUNOCORE HOLDINGS PLC: PRELIMINARY UNAUDITED CASH AND
CASH
EQUIVALENTS IS APPROXIMATELY $443 MILLION USD AS OF DECEMBER 31,
2023
    * IMMUNOCORE HOLDINGS - PURSUING FUTURE GROWTH OPPORTUNITIES
WITH
TWO REGISTRATIONAL TRIALS IN ADVANCED CUTANEOUS MELANOMA AND
ADJUVANT UVEAL MELANOMA
    * IMMUNOCORE HOLDINGS PLC - ADVANCING NOVEL TCR BISPECIFIC
CANDIDATES FOR AUTOIMMUNE DISEASES
    * IMMUNOCORE HOLDINGS PLC: ANTICIPATES THAT EORTC WILL
RANDOMIZE
FIRST PATIENT IN SECOND HALF OF 2024

Source text for Eikon:  ID:nGNXbHJ6Jn 
Further company coverage:  IMCR.O 

 ((Reuters.Briefs@thomsonreuters.com;))